Literature DB >> 26987259

Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?

Catherine Larochelle1, Timo Uphaus2, Alexandre Prat3, Frauke Zipp4.   

Abstract

Prevention of progression in neurological diseases, particularly in multiple sclerosis (MS) but also in neurodegenerative diseases, remains a significant challenge. MS patients switch from a relapsing-remitting to a progressive disease course, but it is not understood why and how this conversion occurs and why some patients never experience disease progression. Do aging and accumulation of neuronal damage induce progression, or do cognitive symptoms and accelerated grey matter (GM) atrophy point to distinct processes affecting networks? This review weighs accepted dogma against real data on the secondary progressive phase of the disease, highlighting current challenges in this important field and directions towards development of treatment strategies to slow or prevent progression of disability.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  conversion; multiple sclerosis; neurodegeneration; progression; secondary progressive; senescence

Mesh:

Year:  2016        PMID: 26987259     DOI: 10.1016/j.tins.2016.02.001

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  28 in total

1.  What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?

Authors:  M M Schoonheim; J J G Geurts
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-27       Impact factor: 3.825

2.  Charting the proteome landscape in major psychiatric disorders: From biomarkers to biological pathways towards drug discovery.

Authors:  Brisa S Fernandes; Yulin Dai; Peilin Jia; Zhongming Zhao
Journal:  Eur Neuropsychopharmacol       Date:  2022-06-25       Impact factor: 5.415

Review 3.  Biological Sex As a Critical Variable in CD4+ Effector T Cell Function in Preclinical Models of Multiple Sclerosis.

Authors:  Muhammad Umair; Mohamed Reda Fazazi; Manu Rangachari
Journal:  Antioxid Redox Signal       Date:  2022-01-04       Impact factor: 7.468

Review 4.  Immunoneuropsychiatry - novel perspectives on brain disorders.

Authors:  Marion Leboyer; Frauke Zipp; Katrin Pape; Ryad Tamouza
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

Review 5.  Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Authors:  Niklas Huntemann; Leoni Rolfes; Marc Pawlitzki; Tobias Ruck; Steffen Pfeuffer; Heinz Wiendl; Sven G Meuth
Journal:  Drugs       Date:  2021-06-04       Impact factor: 9.546

6.  Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis.

Authors:  Susanna Amadio; Chiara Parisi; Eleonora Piras; Paola Fabbrizio; Savina Apolloni; Cinzia Montilli; Sabina Luchetti; Serena Ruggieri; Claudio Gasperini; Franco Laghi-Pasini; Luca Battistini; Cinzia Volonté
Journal:  Front Immunol       Date:  2017-11-15       Impact factor: 7.561

Review 7.  A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.

Authors:  Bert A 't Hart; Jordon Dunham; Bart W Faber; Jon D Laman; Jack van Horssen; Jan Bauer; Yolanda S Kap
Journal:  Front Immunol       Date:  2017-07-11       Impact factor: 7.561

8.  Expression of the Human Herpesvirus 6A Latency-Associated Transcript U94A Disrupts Human Oligodendrocyte Progenitor Migration.

Authors:  Andrew Campbell; Jessica M Hogestyn; Christopher J Folts; Brittany Lopez; Christoph Pröschel; David Mock; Margot Mayer-Pröschel
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

9.  A Unique TGFB1-Driven Genomic Program Links Astrocytosis, Low-Grade Inflammation and Partial Demyelination in Spinal Cord Periplaques from Progressive Multiple Sclerosis Patients.

Authors:  Serge Nataf; Marc Barritault; Laurent Pays
Journal:  Int J Mol Sci       Date:  2017-10-05       Impact factor: 5.923

Review 10.  Multiple sclerosis and drug discovery: A work of translation.

Authors:  Bert A 't Hart; Antonio Luchicchi; Geert J Schenk; Joep Killestein; Jeroen J G Geurts
Journal:  EBioMedicine       Date:  2021-05-24       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.